Showing 6741-6750 of 7742 results for "".
- Revision Skincare Launches DEJ Eye Cream, DEJ Face Creamhttps://practicaldermatology.com/news/revision-launches-dej-eye-cream-dej-face-cream/2457648/Revision Skincare® has created two comprehensive products,DEJ eye cream® and DEJ face cream®, utilizing Pathway Technology and Prebiotic Innovation to provide clinically-proven results and promote long-term skin health, the company says. DEJ eye cream® addresses
- Burt's Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-care-outperforms-md-recommended-regimen/2457650/Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- Neova Introduces Clinical Recovery Creamhttps://practicaldermatology.com/news/neova-introduces-clinical-recovery-cream/2457654/Neova SmartSkinCare is launching its Clinical Recovery range of products. The line of six new products is formulated to keep skin calm, soothed, hydrated, and protected following microdermabrasion, laser resurfacing, chemical peels,K and laser hair removal treatments for increased rates of healin
- FDA Committee Recommends Approval of Paratek's Omadacyclinehttps://practicaldermatology.com/news/fda-committee-recommends-approval-of-parateks-omadacycline/2457656/The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) (17-1) and community-acquired bacterial pneumonia (CABP) (14-4). Paratek Pharmaceuticals,
- Ortho Dermatologics Names 2018 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2018-aspire-higher-scholarship-recipients/2457658/Ortho Dermatologics, a division of Bausch Health Companies Inc., has named the 2018 honorees of the Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine st
- Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Liftshttps://practicaldermatology.com/news/plastic-surgery-groups-issue-warning-on-the-risks-of-brazilian-butt-lifts/2457659/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- Almirall to Acquire Allergan's US Medical Dermatology Unithttps://practicaldermatology.com/news/almirall-to-acquire-allergans-us-medical-dermatology-unit/2457661/Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Ta
- Bonti's Novel Neurotoxin Shines in Early Study of Scar Reduction After Mohs Surgeryhttps://practicaldermatology.com/news/bontis-novel-neurotoxin-shines-in-early-study-of-scar-reduction-after-mohs-surgery/2457662/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- LEO Pharma to Acquire Bayer Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-to-acquire-bayer-prescription-dermatology-business/2457666/LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections, and rosacea and a range of topical steroids with an annual turnover in 2017 o